In the first in ovo tumor challenge study, CAR-T (CD3z-CD28) cells were tested with a single dose of 1 × 105 cells per embryo at each administration, corresponding to an effector-to-tumor ratio (E:T) of 1:1 and 1.67 million cells/kg, either once at EDD11, or twice at EDD11 and EDD14. This evidence concerns the gene CD28 and neoplasm.